Blood test to predict treatment response in esophageal cancer
Part of Cancer, Digestive system clinical trials.
This study uses a simple blood test (called ctDNA) to look for tiny traces of cancer DNA. The goal is to see if this test can predict how well your treatment works, helping doctors tailor care for esophageal cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have esophageal squamous cell carcinoma (a type of esophageal cancer) at stage II, III, or IVA.
- You are at least 18 years old.
- You are able to do light activities or are fully active (ECOG score 0 or 1).
- You have not had surgery for this cancer yet.
- You do not have any other cancer, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether a personalized blood test can detect cancer returning after surgery for esophageal cancer. It tests people who had chemoradiotherapy before surgery and still had some cancer remaining in the removed tissue. The goal is to use the blood test to catch any remaining or returning cancer early.
This trial studies how well “liquid biopsy” blood tests can work in people with newly diagnosed, operable esophageal cancer. It may help doctors monitor the cancer and guide treatment planning alongside standard care.
This study tests a combination of chemotherapy, immunotherapy, and radiation for esophageal cancer that cannot be surgically removed. It also uses a simple blood test (ctDNA) to monitor your cancer's response throughout treatment.
This trial tests whether adjusting treatment based on a blood test (ctDNA) after standard chemoradiation can improve outcomes for patients with advanced esophageal squamous cell carcinoma. It aims to find a more personalized approach to prevent cancer recurrence.
This trial uses a blood test to track genetic changes in esophageal cancer over time. It aims to see if these changes can show how well treatment is working.
This trial tests whether giving chemotherapy after surgery, based on a blood test that finds tiny bits of cancer DNA, can improve outcomes for people with esophageal squamous cell carcinoma. The blood test helps decide who might benefit from extra treatment.
Hear when a new Squamous Cell Carcinoma of Esophagus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.